Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KATHERINE B REED

Allopathic & Osteopathic Physicians Dermatology

NPI
1396919569
CMS profile
335358
Location
SPOKANE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$570.86

34 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $570.86 34

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie Inc. $268.81 16
Lilly USA, LLC $123.21 8
SUN PHARMACEUTICAL INDUSTRIES INC. $45.36 2
UCB, Inc. $41.27 2
Regeneron Healthcare Solutions, Inc. $18.14 1
Amgen Inc. $18.01 1
GENZYME CORPORATION $16.95 1
Novartis Pharmaceuticals Corporation $15.67 1
Allergan, Inc. $12.23 1
PFIZER INC. $11.21 1

Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KATHERINE B REED

NPI 1396919569 · CMS profile ID 335358

Allopathic & Osteopathic Physicians / Dermatology

SPOKANE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396919569?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KATHERINE B REED, NPI 1396919569, CMS profile ID 335358. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396919569?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). KATHERINE B REED, NPI 1396919569, CMS profile ID 335358. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396919569?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
KATHERINE B REED, NPI 1396919569, CMS profile ID 335358, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1396919569?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

34 matching records · $570.86 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 34 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–34 of 34.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $11.2112/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833243081 CMS
AbbVie Inc. $18.4211/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795801731 CMS
UCB, Inc. $16.5111/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807464927 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $25.0811/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851898241 CMS
AbbVie Inc. $26.2210/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795801727 CMS
Lilly USA, LLC $17.1910/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818645537 CMS
Lilly USA, LLC $2.1810/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818623269 CMS
Amgen Inc. $18.0110/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826372609 CMS
AbbVie Inc. $26.4509/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795801723 CMS
Lilly USA, LLC $17.1909/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818617493 CMS
UCB, Inc. $24.7609/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807393497 CMS
AbbVie Inc. $16.7309/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795801719 CMS
AbbVie Inc. $3.8408/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795801715 CMS
AbbVie Inc. $5.0008/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795801711 CMS
Lilly USA, LLC $16.0208/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818629787 CMS
Allergan, Inc. $12.2307/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792918121 CMS
Lilly USA, LLC $16.8007/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818629785 CMS
AbbVie Inc. $4.8707/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795801707 CMS
AbbVie Inc. $26.5607/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795801703 CMS
AbbVie Inc. $5.2806/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795801699 CMS
GENZYME CORPORATION $16.9506/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843607989 CMS
AbbVie Inc. $20.6606/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795801695 CMS
AbbVie Inc. $16.8705/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795801691 CMS
AbbVie Inc. $22.1505/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795801687 CMS
Lilly USA, LLC $16.9605/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818581147 CMS
AbbVie Inc. $28.6804/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795801683 CMS
Regeneron Healthcare Solutions, Inc. $18.1403/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809617167 CMS
Lilly USA, LLC $16.7903/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818581145 CMS
Novartis Pharmaceuticals Corporation $15.6703/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813194857 CMS
AbbVie Inc. $18.2903/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795801679 CMS
Lilly USA, LLC $20.0802/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818581143 CMS
AbbVie Inc. $14.6902/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795801675 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $20.2801/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851898239 CMS
AbbVie Inc. $14.1001/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795801671 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $547.33 32
PY2020 $413.54 18
PY2021 $570.86 34
PY2022 $538.17 34
PY2023 $498.08 30
PY2024 $705.53 35
PY2025 $1,169.72 67

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $734,267.33 246
PY2024 Principal investigator $853,745.12 356
PY2023 Principal investigator $644,757.85 253
PY2022 Principal investigator $361,336.03 142
PY2021 Principal investigator $277,998.71 117
PY2020 Principal investigator $149,365.00 24
PY2019 Principal investigator $53,682.69 24

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

24 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AbbVie, Inc. $4,480.25 12/12/2019 Non-covered Recipient Entity
Dermatology Specialist Of Spokane
M16-045 No dispute reported 06/30/2026 647625983
Principal investigator 1 Incyte Corporation $3,118.94 12/03/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Topical Ruxolitinib Evaluation in Vitiligo Study 1 TRuE-V1A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 666516051
Principal investigator 1 AbbVie, Inc. $4,479.38 11/13/2019 Non-covered Recipient Entity
Dermatology Specialist Of Spokane
M16-045 No dispute reported 06/30/2026 647625985
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $4,500.00 11/04/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701425545
Principal investigator 1 Incyte Corporation $34.25 10/03/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743840569
Principal investigator 1 Incyte Corporation $55.42 10/03/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743840571
Principal investigator 1 Incyte Corporation $69.83 10/03/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743840573
Principal investigator 1 Incyte Corporation $113.02 10/03/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743840575
Principal investigator 1 Incyte Corporation $148.72 10/03/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743840577
Principal investigator 1 Incyte Corporation $169.06 10/03/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743840579
Principal investigator 1 Incyte Corporation $419.92 10/03/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743840581
Principal investigator 1 Incyte Corporation $804.00 10/03/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743840583
Principal investigator 1 Incyte Corporation $5,050.00 09/30/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Topical Ruxolitinib Evaluation in Vitiligo Study 1 TRuE-V1A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 666516033
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $900.00 08/15/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701425537
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $3,900.00 08/15/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701425539
Principal investigator 1 AbbVie, Inc. $8,975.00 08/13/2019 Non-covered Recipient Entity
Dermatology Specialist Of Spokane
M16-045 No dispute reported 06/30/2026 647625987
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $6,064.10 08/12/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701425531
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $3,150.00 05/07/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701425499
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,530.00 04/10/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701425487
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $56.30 04/10/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701425489
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $2,443.50 04/08/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701425477
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $3,163.50 03/01/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701425555
Principal investigator 1 Incyte Corporation $44.29 01/31/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 743840585
Principal investigator 1 Incyte Corporation $13.21 01/31/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 743840591